Evotec SE and Indivumed GmbH have announced that they have entered into a research collaboration to discover and develop first-in-class therapeutics for the treatment of colorectal cancer (“CRC”). The collaboration, which runs for an initial term of two years, will combine Evotec’s proprietary bioinformatics analysis platform “PanHunter” as well as its small molecule and antibody discovery platforms with the CRC cohort of Indivumed’s true multi-omics cancer database “IndivuType”. The goal of this precision medicine collaboration is to deliver highly effective and durable treatments with clear strategies for CRC patient stratification.
Founded in 1993, headquartered in Hamburg, Germany, Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others.
Founded in 2002, Indivumed, a global oncology research company based in Hamburg, Germany, has established the world’s leading multi-omics cancer database and biobank. Proprietary sample collection processes and technology help preserve the integrity of RNA, DNA, and proteins as they existed in the human body. IndivuType, a cancer database, contains vast amounts of genomics, transcriptomics, proteomics, phospho-proteomics and immuno-phenotype imaging information together with clinical and outcome data, making it a unique resource for cancer research in the post-genomics era. Coupled with cutting-edge data analytics, the cancer database can provide deep insights into the underlying mechanisms of a patient’s cancer, addressing important needs in translational research and molecular diagnostics to ultimately deliver personalised cancer healthcare.
Under the terms of the agreement, Evotec has made an undisclosed upfront payment to Indivumed for access to the CRC patient cohort of the IndivuType database. Both parties will jointly invest in data analysis, target identification, validation, and drug discovery. Evotec will be responsible for subsequent partnering of the programmes and/or the platform.
“Evotec is very pleased to partner with Indivumed, who is truly dedicated to developing precision medicine in oncology by generating the most comprehensive multi-omics patient database in oncology that is differentiated from previous datasets due to the higher patient numbers and the application of rigorous quality standards. The access to IndivuType will allow us to identify targets that are matched to CRC subpopulations which have been categorised due to molecular phenotypes and are thus expected to deliver more effective and durable drugs.” – Dr Cord Dohrmann, Chief Scientific Officer of Evotec
“IndivuType is the only true multi-omics database available in the world, enabling break-through insights that lead to new cancer solutions. Our partnership with Evotec fits well with realising our vision of using the multi-omics data within IndivuType to generate new precision medicine therapeutics. We are excited about the prospect of identifying novel drug targets and biomarkers that will help advance and transform CRC patient care. Our team will be attending ASCO where clinicians and researchers will have the opportunity to explore more about IndivuType.” – Prof. Dr Hartmut Juhl, Chief Executive Officer of Indivumed
Sources:
- https://www.biospace.com/article/evotec-and-indivumed-announce-strategic-drug-discovery-collaboration-on-precision-medicine-for-colorectal-cancer-/?keywords=biobank
- https://www.crunchbase.com/organization/evotec-inc#section-overview
- https://www.crunchbase.com/organization/indivumed-gmbh#section-overview
